These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

540 related articles for article (PubMed ID: 23234355)

  • 1. Combined use of anti-ErbB monoclonal antibodies and erlotinib enhances antibody-dependent cellular cytotoxicity of wild-type erlotinib-sensitive NSCLC cell lines.
    Cavazzoni A; Alfieri RR; Cretella D; Saccani F; Ampollini L; Galetti M; Quaini F; Graiani G; Madeddu D; Mozzoni P; Galvani E; La Monica S; Bonelli M; Fumarola C; Mutti A; Carbognani P; Tiseo M; Barocelli E; Petronini PG; Ardizzoni A
    Mol Cancer; 2012 Dec; 11():91. PubMed ID: 23234355
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In pancreatic carcinoma, dual EGFR/HER2 targeting with cetuximab/trastuzumab is more effective than treatment with trastuzumab/erlotinib or lapatinib alone: implication of receptors' down-regulation and dimers' disruption.
    Larbouret C; Gaborit N; Chardès T; Coelho M; Campigna E; Bascoul-Mollevi C; Mach JP; Azria D; Robert B; Pèlegrin A
    Neoplasia; 2012 Feb; 14(2):121-30. PubMed ID: 22431920
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab.
    Chen G; Kronenberger P; Teugels E; Umelo IA; De Grève J
    BMC Med; 2012 Mar; 10():28. PubMed ID: 22436374
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined Erlotinib and Cetuximab overcome the acquired resistance to epidermal growth factor receptors tyrosine kinase inhibitor in non-small-cell lung cancer.
    Wang M; Zhao J; Zhang LM; Li H; Yu JP; Ren XB; Wang CL
    J Cancer Res Clin Oncol; 2012 Dec; 138(12):2069-77. PubMed ID: 22821179
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Beneficial effect of erlotinib and trastuzumab emtansine combination in lung tumors harboring EGFR mutations.
    Kayatani H; Ohashi K; Ninomiya K; Makimoto G; Nishii K; Higo H; Watanabe H; Kano H; Kato Y; Ninomiya T; Kubo T; Rai K; Ichihara E; Hotta K; Tabata M; Maeda Y; Kiura K
    Biochem Biophys Res Commun; 2020 Nov; 532(3):341-346. PubMed ID: 32888648
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Addition of bevacizumab enhances antitumor activity of erlotinib against non-small cell lung cancer xenografts depending on VEGF expression.
    Li H; Takayama K; Wang S; Shiraishi Y; Gotanda K; Harada T; Furuyama K; Iwama E; Ieiri I; Okamoto I; Nakanishi Y
    Cancer Chemother Pharmacol; 2014 Dec; 74(6):1297-305. PubMed ID: 25344762
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lapatinib enhances trastuzumab-mediated antibody-dependent cellular cytotoxicity via upregulation of HER2 in malignant mesothelioma cells.
    Okita R; Shimizu K; Nojima Y; Yukawa T; Maeda A; Saisho S; Nakata M
    Oncol Rep; 2015 Dec; 34(6):2864-70. PubMed ID: 26503698
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance.
    Naumov GN; Nilsson MB; Cascone T; Briggs A; Straume O; Akslen LA; Lifshits E; Byers LA; Xu L; Wu HK; Jänne P; Kobayashi S; Halmos B; Tenen D; Tang XM; Engelman J; Yeap B; Folkman J; Johnson BE; Heymach JV
    Clin Cancer Res; 2009 May; 15(10):3484-94. PubMed ID: 19447865
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epidermal growth factor receptor (EGFR) targeted therapies in non-small cell lung cancer (NSCLC).
    Metro G; Finocchiaro G; Toschi L; Bartolini S; Magrini E; Cancellieri A; Trisolini R; Castaldini L; Tallini G; Crino L; Cappuzzo F
    Rev Recent Clin Trials; 2006 Jan; 1(1):1-13. PubMed ID: 18393776
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combining onartuzumab with erlotinib inhibits growth of non-small cell lung cancer with activating EGFR mutations and HGF overexpression.
    Sano Y; Hashimoto E; Nakatani N; Abe M; Satoh Y; Sakata K; Fujii T; Fujimoto-Ouchi K; Sugimoto M; Nagahashi S; Aoki M; Motegi H; Sasaki E; Yatabe Y
    Mol Cancer Ther; 2015 Feb; 14(2):533-41. PubMed ID: 25522765
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The HSP90 inhibitor ganetespib potentiates the antitumor activity of EGFR tyrosine kinase inhibition in mutant and wild-type non-small cell lung cancer.
    Smith DL; Acquaviva J; Sequeira M; Jimenez JP; Zhang C; Sang J; Bates RC; Proia DA
    Target Oncol; 2015 Jun; 10(2):235-45. PubMed ID: 25077897
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance.
    Cretella D; Saccani F; Quaini F; Frati C; Lagrasta C; Bonelli M; Caffarra C; Cavazzoni A; Fumarola C; Galetti M; La Monica S; Ampollini L; Tiseo M; Ardizzoni A; Petronini PG; Alfieri RR
    Mol Cancer; 2014 Jun; 13():143. PubMed ID: 24898067
    [TBL] [Abstract][Full Text] [Related]  

  • 13. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
    Greenhalgh J; Dwan K; Boland A; Bates V; Vecchio F; Dundar Y; Jain P; Green JA
    Cochrane Database Syst Rev; 2016 May; (5):CD010383. PubMed ID: 27223332
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of histone deacetylases sensitizes EGF receptor-TK inhibitor-resistant non-small-cell lung cancer cells to erlotinib in vitro and in vivo.
    Yu W; Lu W; Chen G; Cheng F; Su H; Chen Y; Liu M; Pang X
    Br J Pharmacol; 2017 Oct; 174(20):3608-3622. PubMed ID: 28749535
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Erlotinib is a viable treatment for tumors with acquired resistance to cetuximab.
    Brand TM; Dunn EF; Iida M; Myers RA; Kostopoulos KT; Li C; Peet CR; Wheeler DL
    Cancer Biol Ther; 2011 Sep; 12(5):436-46. PubMed ID: 21725209
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Focal Adhesion Kinase Inhibitors in Combination with Erlotinib Demonstrate Enhanced Anti-Tumor Activity in Non-Small Cell Lung Cancer.
    Howe GA; Xiao B; Zhao H; Al-Zahrani KN; Hasim MS; Villeneuve J; Sekhon HS; Goss GD; Sabourin LA; Dimitroulakos J; Addison CL
    PLoS One; 2016; 11(3):e0150567. PubMed ID: 26962872
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination of betulinic acid and EGFR-TKIs exerts synergistic anti-tumor effects against wild-type EGFR NSCLC by inducing autophagy-related cell death via EGFR signaling pathway.
    Wang H; Du X; Liu W; Zhang C; Li Y; Hou J; Yu Y; Li G; Wang Q
    Respir Res; 2024 May; 25(1):215. PubMed ID: 38764025
    [TBL] [Abstract][Full Text] [Related]  

  • 18. JAK2 inhibitor TG101348 overcomes erlotinib-resistance in non-small cell lung carcinoma cells with mutated EGF receptor.
    Zhang FQ; Yang WT; Duan SZ; Xia YC; Zhu RY; Chen YB
    Oncotarget; 2015 Jun; 6(16):14329-43. PubMed ID: 25869210
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The autophagy inhibitor chloroquine overcomes the innate resistance of wild-type EGFR non-small-cell lung cancer cells to erlotinib.
    Zou Y; Ling YH; Sironi J; Schwartz EL; Perez-Soler R; Piperdi B
    J Thorac Oncol; 2013 Jun; 8(6):693-702. PubMed ID: 23575415
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Continuous inhibition of epidermal growth factor receptor phosphorylation by erlotinib enhances antitumor activity of chemotherapy in erlotinib-resistant tumor xenografts.
    Iwai T; Moriya Y; Shirane M; Fujimoto-Ouchi K; Mori K
    Oncol Rep; 2012 Apr; 27(4):923-8. PubMed ID: 22209766
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.